Skip to content

EBIT at other companies

PTC Therapeutics logo
PTC TherapeuticsPTCT
$44.96M-95.4%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
-$36.92M+13.5%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$103.61M-38.3%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$52.36M-11.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Arrowhead Research logo
Arrowhead ResearchARWR

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Return on equity-138.9%+60.1pp
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Calculated from Scholar Rock’s reported figures.

Plus components not separately reported this period.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's EBIT?
Scholar Rock (SRRK) reported EBIT of -$102.02M in Q1 2026.
How has Scholar Rock's EBIT changed year-over-year?
Scholar Rock's EBIT decreased by 32.3% year-over-year, from -$77.09M to -$102.02M.
What is the long-term trend for Scholar Rock's EBIT?
Over 4 years (2021 to 2025), Scholar Rock's EBIT has grown at a 31.2% compound annual growth rate (CAGR), from -$129.92M to -$384.65M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.